KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Common Equity (2016 - 2025)

Historic Common Equity for Amgen (AMGN) over the last 17 years, with Q3 2025 value amounting to $9.6 billion.

  • Amgen's Common Equity rose 2779.33% to $9.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.6 billion, marking a year-over-year increase of 2779.33%. This contributed to the annual value of $5.9 billion for FY2024, which is 569.64% down from last year.
  • Amgen's Common Equity amounted to $9.6 billion in Q3 2025, which was up 2779.33% from $7.4 billion recorded in Q2 2025.
  • Over the past 5 years, Amgen's Common Equity peaked at $9.6 billion during Q3 2025, and registered a low of $916.0 million during Q1 2022.
  • Over the past 5 years, Amgen's median Common Equity value was $6.2 billion (recorded in 2023), while the average stood at $6.1 billion.
  • Per our database at Business Quant, Amgen's Common Equity tumbled by 9018.64% in 2022 and then surged by 48384.28% in 2023.
  • Quarter analysis of 5 years shows Amgen's Common Equity stood at $6.7 billion in 2021, then crashed by 45.36% to $3.7 billion in 2022, then soared by 70.23% to $6.2 billion in 2023, then dropped by 5.7% to $5.9 billion in 2024, then surged by 63.67% to $9.6 billion in 2025.
  • Its Common Equity was $9.6 billion in Q3 2025, compared to $7.4 billion in Q2 2025 and $6.2 billion in Q1 2025.